Evidence map›Paper›PMID 36903376›Full record

ArticleMolecules (Basel, Switzerland)2023

Ultrasound-Assisted Synthesis of Piperidinyl-Quinoline Acylhydrazones as New Anti-Alzheimer's Agents: Assessment of Cholinesterase Inhibitory Profile, Molecular Docking Analysis, and Drug-like Properties.

Rubina Munir, Sumera Zaib, Muhammad Zia-Ur-Rehman, Nadia Hussain, Faryal Chaudhry, Muhammad Tayyab Younas, Fatima Tuz Zahra, Zainab Tajammul, Noman Javid, Ayed A Dera and 2 more

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rubina MunirSchool of Chemistry, University of the Punjab, Lahore 54590, Pakistan.ORCID 0000-0001-8015-5974
Sumera ZaibDepartment of Basic and Applied Chemistry, Faculty of Science and Technology, University of Central Punjab, Lahore 54590, Pakistan.
Muhammad Zia-Ur-RehmanApplied Chemistry Research Centre, PCSIR Laboratories Complex, Lahore 54600, Pakistan.ORCID 0000-0001-6208-4527
Nadia HussainDepartment of Pharmaceutical Sciences, College of Pharmacy, Al Ain University, Al Ain P.O. Box 64141, United Arab Emirates.ORCID 0000-0001-6314-2485
Faryal ChaudhryDepartment of Chemistry, Kinnaird College for Women, Lahore 54000, Pakistan.ORCID 0000-0002-7101-0850
Muhammad Tayyab YounasDepartment of Basic and Applied Chemistry, Faculty of Science and Technology, University of Central Punjab, Lahore 54590, Pakistan.ORCID 0000-0002-2300-7331
Fatima Tuz ZahraDepartment of Chemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Zainab TajammulDepartment of Basic and Applied Chemistry, Faculty of Science and Technology, University of Central Punjab, Lahore 54590, Pakistan.
Noman JavidChemistry Department (C-Block), Forman Christian College, Ferozepur Road, Lahore 54600, Pakistan.
Ayed A DeraDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha 62529, Saudi Arabia.ORCID 0000-0002-6248-8983
Hanan A OgalyChemistry Department, College of Science, King Khalid University, Abha 61421, Saudi Arabia.ORCID 0000-0002-0480-5127
Imtiaz KhanDepartment of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, Manchester M1 7DN, UK.ORCID 0000-0001-7359-1727

Funding

King Khalid University RGP.1/282/43
6 · The paper itself

Abstract

Alzheimer's disease (AD) is one of the progressive neurological disorders and the main cause of dementia all over the world. The multifactorial nature of Alzheimer's disease is a reason for the lack of effective drugs as well as a basis for the development of new structural leads. In addition, the appalling side effects such as nausea, vomiting, loss of appetite, muscle cramps, and headaches associated with the marketed treatment modalities and many failed clinical trials significantly limit the use of drugs and alarm for a detailed understanding of disease heterogeneity and the development of preventive and multifaceted remedial approach desperately. With this motivation, we herein report a diverse series of piperidinyl-quinoline acylhydrazone therapeutics as selective as well as potent inhibitors of cholinesterase enzymes. Ultrasound-assisted conjugation of 6/8-methyl-2-(piperidin-1-yl)quinoline-3-carbaldehydes (

Indexed as

Alzheimer DiseaseQuinolinesAcetylcholinesteraseCholinesterase InhibitorsCholinesterasesHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAcetylcholinesteraseCholinesterase InhibitorsCholinesterasesQuinolinesAlzheimer’s diseasecholinesterasesmolecular dockingN-acylhydrazoneneurological disorderphysicochemical propertiespiperidinequinoline

Identifiers

PMID36903376
PMCPMC10004187

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read173
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.